DSY Dassault Systemes SA

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey 

Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care

New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration with Sanofi in clinical research. As part of this extension Sanofi will use the , building on the organizations’ vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge can help advance studies, amplifying the development of therapies with greater precision and impact.

Sanofi will employ Medidata’s expertise and capabilities in as part of the extension of this agreement. Medidata will provide consulting and end-to-end operational support.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through this agreement, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the clinical development process.”

To learn more about the Medidata Experiences, please visit .

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at . Listen to our latest podcast, , and follow us at @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

Contact:

Medidata PR

Analyst Relations

Attachment



EN
28/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

 PRESS RELEASE

Dassault Systèmes: Half-year statement of the Liquidity contract enter...

Dassault Systèmes: Half-year statement of the Liquidity contract entered into with Oddo BHF SCA Press ReleaseVELIZY-VILLACOUBLAY, France — January 12, 2026 Half-year statement of the Liquidity contract entered into with Oddo BHF SCA (Euronext Paris: FR0014003TT8, DSY.PA) announces that the following resources appeared on December 31, 2025 on the liquidity contract entered into with Oddo BHF SCA implemented on January 7, 2015 and updated on June 18, 2019:      925,197 Dassault Systèmes shares, and€ 5,384,754.01 in cash. It is reminded that: at the time of the implementation of the liqu...

 PRESS RELEASE

Dassault Systèmes : Bilan Semestriel du Contrat de Liquidité conclu av...

Dassault Systèmes : Bilan Semestriel du Contrat de Liquidité conclu avec Oddo BHF SCA Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 12 janvier 2026 Bilan Semestriel du Contrat de Liquidité conclu avec Oddo BHF SCA (Euronext Paris : FR0014003TT8, DSY.PA) annonce qu’au titre du contrat de liquidité confié à Oddo BHF SCA mis en œuvre depuis le 7 janvier 2015 et mis à jour le 18 juin 2019, les moyens suivants figuraient au compte de liquidité à la date du 31 décembre 2025 : 925 197 actions Dassault Systèmes, et5 384 754,01 € en espèces. Il est rappelé : qu’à l’ouverture du contrat ...

 PRESS RELEASE

Declaration of the number of outstanding shares and voting rights as ...

Declaration of the number of outstanding shares and voting rights as of December 31, 2025 Press ReleaseVELIZY-VILLACOUBLAY, France — January 7, 2026                 Declaration of the number of outstanding shares and voting rights as of December 31, 2025 (Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of December 31, 2025, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares: 1,341,806,268 Number of voting rights*: 2,013,578,477 ...

 PRESS RELEASE

Déclaration du nombre d’actions et de droits de vote au 31 décembre 20...

Déclaration du nombre d’actions et de droits de vote au 31 décembre 2025 Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 7 janvier 2026 Déclaration du nombre d’actions et de droits de voteau 31 décembre 2025         (Euronext Paris : FR0014003TT8, DSY.PA) annonce ci-après le nombre total d’actions composant son capital et le nombre total de ses droits de vote au 31 décembre 2025, conformément aux articles 223-16 et 221-3 du Règlement Général de l’Autorité des marchés financiers. Nombre d'actions en circulation : 1 341 806 268 Nombre de droits de vote* : 2 013 578 477 *Ce nombre t...

Dassault Systemes Sa: 1 director

A director at Dassault Systemes Sa bought 32,355 shares at 23.075EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch